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Abstract
Background: Serious skin disorders have been associated with the use of oral antifungals in a
number of case reports and series of cases. However the incidence of these disorders remains
unknown.
Methods: We estimated the risk of serious skin disorders in a cohort of users of oral antifungals
identified in the general population of the General Practice Research Database in the UK. The
cohort included 61,858 patients, 20 to 79 years old, who had received at least one prescription for
either oral fluconazole, griseofulvin, itraconazole, ketoconazole, or terbinafine.
Results: The background rate of serious cutaneous adverse reactions (the one corresponding to
non use of oral antifungals) was 3.9 per 10,000 person-years (95% CI 2.9–5.2). Incidence rates for
current use were 15.4 per 10,000 person-years (1.9–55.7) for itraconazole, 11.1 (3.0–28.5) for
terbinafine, 10.4 (1.3–37.5) for fluconazole, and 4.6 (0.1–25.8) for griseofulvin. Itraconazole was the
antifungal associated with the highest relative risk, 3.9 (0.5–15.0), when compared to the risk
among non users, followed by terbinafine and fluconazole, with relative risks of 2.8 (0.7–7.8) and
2.6 (0.3–10.1), respectively.
Conclusions: We conclude that cutaneous disorders associated with the use of oral antifungals in
this study were all of mild severity and that the risk associated with the use of oral antifungals was
slightly higher than the risk in non-users. The safety profile of terbinafine regarding cutaneous
disorders is similar to other antifungals and in the very low range of risks associated with other
drugs.
Background
Serious skin disorders including toxic epidermal necroly-
sis, Stevens-Johnson syndrome, erythema multiforme, an-
gioedema and acute generalized exanthematous
pustulosis have been associated with the use of oral anti-
fungals in a number of case reports and retrospective se-
ries of cases. However, studies examining the risk
associated with the use of oral antifungal drugs are not
available.
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In the present study we estimated the risk of potentially
serious skin disorders in a cohort of users of oral antifun-
gals identified in the general population of UK using the
General Practice Research Database (GPRD).
Population and methods
Source population
The GPRD contains clinical computerized information
entered in a standardized manner by general practitioners
(GPs) on their patients. Around 1,500 GPs, covering a
population exceeding 3 million, have agreed to provide
systematically their data files anonymously to the Office
of National Statistics (ONS) and to allow the information
to be used for research purposes.[1] Upon receiving the
data from the GPs, ONS organizes this information and
performs a series of quality checks. The computerized in-
formation includes demographics, details of each visit, a
summary of specialists' clinical notes and hospital letters,
results of laboratory tests and a free text section. A modi-
fication of the Oxford Medical Information System (OX-
MIS) classification system is used to code specific
diagnoses, and a drug dictionary based on data from the
Prescription Pricing Authority is used to code drugs.[2]
Prescriptions issued by the general practitioner are directly
generated by the computer system with dosage instruc-
tions included. Also, the indication for treatment is re-
quired for all new courses of therapy. Recorded
information can be validated and completed through re-
view of original paper-based medical records. Validation
studies with the GPRD have documented the recording of
medical data in the GP's computers to be near to com-
plete.[3,4]
Study cohort
The study cohort comprised all patients aged 20–79 who
had received at least one prescription for either oral fluco-
nazole, griseofulvin, itraconazole, ketoconazole, or ter-
binafine between January 1, 1991 and March 31, 1997.
We excluded all patients with a prior history of diseases or
conditions predisposing to cutaneous disorders including
neoplasms, AIDS, and systemic and immunosupressive
disorders and therapies. Patients with a previous history
of skin disorders were similarly excluded. The final study
cohort was constituted by 61,858 patients. We followed-
up each patient in the study cohort from the date of the
first antifungal drug prescription until the earliest occur-
rence of: a) code for any of the study endpoints: toxic ep-
idermal necrolysis, Stevens-Johnson syndrome, erythema
multiforme, angioedema, or acute generalized exanthe-
matous pustulosis; b) one of the exclusion conditions
mentioned above; c) age greater than 80; d) death; or e)
date of end of the study period.
Case definition and ascertainment
In a first step we identified potential cases through an au-
tomated search for the OXMIS codes listed in table 1. The
computerized information of these potential cases was
manually reviewed to discard patients with any of the
study exclusion criteria: neoplasms, AIDS, and systemic
and immunosupressive disorders and therapies. The re-
maining cases were validated through a structured ques-
tionnaire administered to the GPs along with review of all
medical records provided anonymously by the GPs. All
the process of case identification and validation was done
blindly to the use of medications.
We defined as a case of potentially serious skin disorder
any patient in the study cohort with a first ever diagnosis
of toxic epidermal necrolysis, Stevens-Johnson syndrome,
erythema multiforme, angioedema, or acute generalized
exanthematous pustulosis, recorded in the database dur-
ing the study period. We required confirmation of the di-
agnosis based on the questionnaire filled by the GP and
the review of medical records when available.
Exposure definition
Person time at risk was aggregated in three different time
windows according to use of the study antifungal drugs.
Current use encompassed all the days of prescribed treat-
ment plus an additional period of 14 days at the end of
treatment. Past use was defined as the period of 90 days
following the time window of current use. Finally, the
time period starting after past use was defined as non use.
Analysis
Incidence rates of serious skin disorders were calculated
using as denominator both the number of patients ex-
posed to each individual antifungal drug and the corre-
Table 1: OXMIS codes used for case identification
OXMIS code Diagnosis
6951 Erythema multiforme
6951 Erythema multiforme exudativum
6951 Syndrome Stevens-Johnson
6951 Necrolysis toxic epidermal
L7090 Lyell's disease
L7090 Epidermal necrolysis
6869 Eczema pustular
7882 Rash pustular
7080 Angioneurotic oedema
7080 Angio-oedema
7080 Oedema Quincke's
7080 Oedema supraglotic allergic
6959 Dermatitis exfoliative
9779 Eruption skin due drug ingestedBMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/14
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sponding person-time at risk. Ninety-five percent
confidence intervals were computed on the basis of a Pois-
son distribution of case counts within categories of use.[5]
The Stata program was used to obtain estimates of rate ra-
tios.[6]
Results
A total of 61,858 patients received 120,807 prescriptions
for oral antifungals. The age and sex distribution of the
study cohort is presented in table 2. Fluconazole, itraco-
nazole, and ketoconazole were mainly prescribed to
young women, whereas griseofulvin and terbinafine were
predominantly prescribed to middle aged men.
We identified 113 potential cases of serious skin disor-
ders. Of these, 26 (23%) were excluded after review of
their computerized information. Medical records were re-
quested to the GPs for the remaining 87 patients. Review
of medical records led to confirm 62 cases and to exclude
25 additional patients. For three of these excluded pa-
tients medical records were not available. The reasons of
exclusion after the review of both computerized informa-
tion and medical records are summarized in table 3.
Of the 62 confirmed cases, 47 (76%) occurred during the
period of non use of oral antifungals, 6 (10%) during past
use, and 9 (14%) during current use. Specific diagnostics
for the three categories of use are presented in table 4. An-
gioedema was the more frequent disorder (65%), fol-
lowed by erythema multiforme (21%). There were two
cases of Stevens-Johnson syndrome and one case of der-
matitis exfoliative. No cases of toxic epidermal necrolysis
and acute generalized exanthematous pustulosis were
identified. None of the 62 cases was life-threatening. Most
cases (69%) were diagnosed and managed by the GP, 17
cases (27%) by the dermatologist, and two (3%) required
hospitalization. These two cases with hospitalization oc-
curred among non-users of oral antifungals.
Rates in non-users
The overall background rate corresponding to non-users
of oral antifungals was 3.9 per 10,000 person-years (95%
CI 2.9–5.2). Among non-users there were 32 (68%) cases
with angioedema, 13 (28%) with erythema multiforme, 1
(2%) with dermatitis exfoliative, and 1 (2%) Stevens-
Johnson syndrome. Most cases (68%) were diagnosed
Table 2: Age and sex distribution of the study cohort of users of oral antifungals*
Fluconazole Griseofulvin Itraconazole Ketoconazole Terbinafine
n % n % n % n % n %
Sex
Women 24,236 (90) 2,003 (41) 11,474 (75) 394 (53) 6,017 (43)
Men 2,756 (10) 2,938 (59) 3,855 (25) 343 (47) 7,842 (57)
Age
20–39 13,742 (51) 1,585 (32) 7,678 (50) 334 (45) 3,927 (28)
40–59 10,340 (38) 2,210 (45) 5,848 (38) 267 (36) 6,281 (45)
60–69 1,767 (7) 737 (15) 1,150 (8) 91 (12) 2,338 (17)
70–79 1,143 (4) 409 (8) 653 (4) 45 (6) 1,313 (9)
Total 26,992 4,491 15,329 737 13,859
* Some of the cohort members received more than one antifungal drug during the study period.
Table 3: Exclusions after review of computer patient profiles and 
medical records
Diagnosis not confirmed 6
Other skin disorders 36
Rash 23
Focalized eczema 7
Acne 1
Erysipela 1
Pityriasis rosacea 1
Lichen planus 1
Candidiasis 1
Benign dermatofibroma 1
Prior history 4
Exclusion criteria* 2
Medical record not available 3
Total excluded 51
*One patient had a bronchogenic carcinoma and the other was HIV 
positiveBMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/14
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and managed by the general practitioner, 13 (28%) by the
dermatologist and 2 (4%) required hospitalization. These
two last cases were hospitalized because of angioedema.
The two cases of dermatitis exfoliative and Stevens-John-
son syndrome were both diagnosed by the general practi-
tioner.
Rates in current users
For current users, two cases occurred during treatment
with fluconazole (one angioedema and one erythema
multiforme), one with griseofulvin (angioedema), two
with itraconazole (one angioedema and one erythema
multiforme) and four with terbinafine (two cases with an-
gioedema, one with erythema multiforme, and one with
Stevens-Johnson syndrome) (table 5). The case with Ste-
vens-Johnson syndrome was diagnosed and managed by
the general practitioner without requiring hospitalization.
Concurrent treatment with drugs potentially related with
serious skin disorders was found in two patients, both
with angioedema. One exposed to griseofulvine was tak-
ing cefalexine and diclofenac and the other with current
use of itraconazole was concurrently treated with pred-
nisolone.
Incidence rates of serious cutaneous disorders for current
use of individual antifungal drugs are presented in table 6.
The highest rate was for itraconazole (15.4 per 10,000 per-
son-years), followed by terbinafine (11.1 per 10,000 per-
son-years), fluconazole (10.4 per 10,000 person-years),
and griseofulvin (4.6 per 10,000 person-years). Itracona-
zole was the antifungal drug associated with the greatest
relative risk (3.9, 95% CI 0.5–15.0) compared to the back-
ground risk of non users, followed by terbinafine (2.8,
95% CI 0.7–7.8) and fluconazole (2.6, 95% CI 0.3–10.1).
Table 4: Serious skin disorders according to source of diagnosis
Source of diagnosis Diagnosis Current use Past use Non use Overall
General practitioner Angioedema 3 2 24 29
Erythema multiforme 3 2 6 11
Stevens-Johnson syndrome 1 0 1 2
Dermatitis exfoliative 0 0 1 1
Dermatologist A n g i o e d e m a 21 69
Erythema multiforme 0 1 7 8
Hospitalization A n g i o e d e m a 00 22
Total 9 6 47 62
Table 5: Characteristics of cases of serious skin disorders with current exposure to oral antifungals
Current use Age Sex Duration of 
treatment 
(days)
Dose 
(mg)
Diagnosis Source of 
diagnosis
Co-medication potentially 
related with serious skin 
disorders
Fluconazole 45 F 18 50 Angioedema Dermatologist None
Fluconazole 20 F 1 150 Erythema multiforme GP None
Griseofulvin 55 M 50 500 Angioedema GP Cefalexine, diclofenac
Itraconazole 35 F 58 100 Angioedema Dermatologist Prednisolone
Itraconazole 63 M 6 100 Erythema multiforme GP None
Terbinafine 64 M 172 250 Angioedema Dermatologist None
Terbinafine 35 F 75 250 Angioedema GP None
Terbinafine 56 M 26 250 Stevens-Johnson syndrome GP None
Terbinafine 27 F 6 250 Erythema multiforme GP None
M = Male; F = Female;GP = General PractitionerBMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/14
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Rates in past users
Of the six cases with past use of oral antifungals four had
been exposed to terbinafine (two with angioedema and
two with erythema multiforme) and two to fluconazole
(one angioedema and one erythema multiforme) (table
7). The number of days from the end of treatment with
oral antifungals to start of symptoms ranged from 16 to
77 for past users of terbinafine. The number of days were
43 and 55 for the two past users of fluconazole. Current
use of other drugs potentially related with serious skin dis-
orders was found in two patients with past exposure to ter-
binafine and in one patient with past use of fluconazole.
The incidence rate of serious skin disorders for past users
of terbinafine was 11.1 per 10,000 person-years (95% CI
3.0–28.3) and that for past users of fluconazole 2.1 (0.3–
7.7). The corresponding relative risk compared to the rate
in non-users were 2.8 (1.0–7.8) for terbinafine and 0.5
(0.1–2.2) for fluconazole (table 7).
Discussion
In this study we estimated the risk of serious skin disor-
ders in a cohorts of 61,858 users of oral antifungals. Of
the 62 confirmed cases 9 occurred among current users, 6
among past users, and 47 among non-users of oral anti-
fungals. The risk associated with individual current use of
antifungals, as compared to non-use, were 1.2 for griseof-
ulvine, 2.6 for fluconazole, 2.8 for terbinafine, and 3.9 for
itraconazole. All these relative risks were based on a very
small number of exposed cases, between one and four,
and the confidence intervals were wide, not statistically
significant, and overlapped among them.
The selected skin disorders assessed in this study are those
commonly considered as potentially severe or life-threat-
ening. However, the potential for severity is highly varia-
ble among the different disorders and also within a same
condition. Toxic epidermal necrolysis is perhaps the most
severe dermatosis and we did not identify any case neither
in exposed nor in non-exposed patients.
Most of the cases identified in this study were not severe
enough to require hospitalization and none was life-
threatening. Only two cases of angioedema, which oc-
curred among non-users of antifungals, had to be hospi-
talized. All exposed cases were treated by the general
practitioner or by the dermatologist. This indicates that se-
Table 6: Crude incidence rates of serious skin disorders among current users of oral antifungals
Antifungal Patients Person-
years
Cases Cumulative incidence per 
10,000 patients
Incidence rate per 10,000 
person-years
Relative risk* (95% CI)
Fluconazole 26,992 1,927 2 0.7 (0.01–2.7) 10.4 (1.3–37.5) 2.6 (0.3–10.1)
Griseofulvin 4,941 2,158 1 2.0 (0.1–11.3) 4.6 (0.1–25.8) 1.2 (0.03–6.9)
Itraconazole 15,329 1,296 2 1.3 (0.2–4.7) 15.4 (1.9–55.7) 3.9 (0.5–15.0)
Ketoconazole 737 89 0 0.0 (0.0–50.1) 0.0 (0.0–414.3) 0.0 (0.0–109.9)
Terbinafine 13,859 3,596 4 2.9 (0.8–7.4) 11.1 (3.0–28.5) 2.8 (0.7–7.8)
CI = Confidence interval * Incidence rate ratio using non-use person-time as the reference category.
Table 7: Characteristics of cases of serious skin disorders with past exposure to oral antifungals
Past use Age Sex Duration of 
treatment 
(days)
Days from last 
dose intake to 
initial symptoms
Dose 
(mg)
Diagnosis Source of 
diagnosis
Current use with drugs 
potentially related with 
serious skin disorders
Fluconazole 57 F 1 43 150 Erythema multiforme Dermatologist Cefaclor
Fluconazole 37 F 1 55 150 Angioedema GP None
Terbinafine 76 M 196 16 250 Angioedema Dermatologist Claritromicine
Terbinafine 46 F 28 63 250 Angioedema GP None
Terbinafine 47 F 28 77 250 Erythema multiforme GP Flucoxacilline
Terbinafine 48 M 14 28 250 Erythema multiforme GP None
M = Male; F = Female;GP = General PractitionerBMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/14
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vere, life-threatening skin disorders associated with the
use of oral antifungals are extremely rare.
A consideration to this study is the potential for misclassi-
fication of specific diagnostics. Although cases identified
were validated by asking to the corresponding general
practitioner confirmation of the diagnosis, we did not as-
sess the clinical characteristics of the specific skin disorder.
This could result in misclassification of diagnostics partic-
ularly among those cases not referred to the dermatolo-
gist. Also, some forms of cutaneous reactions are
sometimes difficult to differentiate among them specially
in those cases with mild severity. Thus, misclassification
could occur between the diagnosis of erythema multi-
forme and mild forms of Stevens-Johnson syndrome.
We defined current use of antifungals as all the days of
prescribed treatment plus an additional period of two
weeks after the end of treatment. Most cutaneous adverse
reactions to drugs occur during the first three or four
weeks of treatment.[7] With the additional period of two
weeks after the end of treatment we ensured the capture of
disorders appearing at the very end of treatment. For past
use of oral antifungals we considered a period of 90 days
after the end of the current use time window. The ration-
ale for including a period of past use in pharmacoepide-
miological studies is to examine drug effects with late
onset that is with a long latency period. However, it is con-
sidered that adverse cutaneous reactions to drugs mainly
occur during the period of active treatment. Thus, attribu-
tion of cutaneous disorders to the past use of specific
drugs is more problematic and difficult to interpret than
attribution to, active treatment.
Regarding terbinafine the risk of skin disorders was about
three times higher than the risk in non-users and similar
to the risk of other antifungals. This relative risk lies in the
very low range of risks of severe skin disorders associated
to other drugs. In an international case-control study the
highest relative risks of Stevens-Johnson syndrome and
toxic epidermal necrolysis for drugs ususally used for
short periods were 172 for sulfonamides, 160 for trimeth-
roprim-sulfamethoxazole, 62 for chlormezanone, 14 for
cephalosporins, 10 for quinolones, and 6.7 for ami-
nopenicillines.[8] Among drugs used for months or years
the highest relative risks were for anti-epileptics (RR be-
tween 25 and 90), oxicam NSAIDs (RR = 72), allopurinol
(RR = 52), and corticosteroids (RR = 54).[8,9] The
number of cases of Stevens-Johnson syndrome and epi-
dermal necrolysis attributable to the use of medications
ranged from 0.2 cases per million for aminopenicillines
and tetracyclines, to 4.5 cases per million for sulfona-
mides.[8]
Conclusions
We conclude that cutaneous disorders associated with the
use of oral antifungals in this study were all of mild sever-
ity and that the risk associated with the use of oral antifun-
gals was slightly higher than the risk in non-users. The
safety profile of terbinafine regarding cutaneous disorders
is similar to other antifungals and in the very low range of
risks associated with other drugs.
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